In support of the functional consequences of these human tumor findings, an unbiased RNAi-based forward genetic screen also identified PLK2 as one of the candidate tumor suppressors in breast cancer (Fig. 1E; refs. 37, 38). Here, PLK2 is linked to breast carcinoma.